Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Kentaro Yamazaki; Takeharu Yamanaka; Manabu Shiozawa; Dai Manaka; Masahito Kotaka; Makio Gamoh; Akio Shiomi; Akitaka Makiyama; Yoshinori Munemoto; T. Rikiyama; Masashi Fukunaga; T. Ueki; Kohei Shitara; Hiroshi Shinkai; Nobuyuki Tanida; Eiji Oki; Eiji Sunami; Atsushi Ohtsu; Yoshihiko Maehara; Takayuki Yoshino

doi:10.1016/j.annonc.2020.10.480

Key Points

The ACHIEVE-2 trial aims to determine whether reducing oxaliplatin-based adjuvant chemotherapy from six months to three months preserves therapeutic efficacy in high-risk stage II colon cancer.
Randomized phase III interventional clinical trial registered under UMIN000013036 and jRCTs031180128.
Evaluated patients with resected high-risk stage II colon cancer assigned to either 3 months or 6 months of oxaliplatin-based adjuvant chemotherapy.
Primary efficacy metrics, event rates, and hazard ratios are not reported in the brief registry summary text.
The comparative assessment focuses on disease recurrence rates alongside the reduction of cumulative oxaliplatin-induced peripheral neuropathy.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Investigates three versus six months of oxaliplatin chemotherapy in high-risk stage II colon cancer, highlighting efforts to optimize treatment duration.

Abstract

UMIN Clinical Trials Registry, UMIN000013036 and Japan Registry of Clinical Trials, jRCTs031180128.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yamazaki et al. (2020) studied this question.

synapsesocial.com/papers/69d7cd3961e2ce1627d18134 https://doi.org/10.1016/j.annonc.2020.10.480

View Full Paper

Ask AI

Bookmark

Share

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading